Navigation Links
Signalife Awarded New U.S. Patent, 'System For, And Method Of, Monitoring Heartbeats Of A Patient'
Date:4/23/2008

GREENVILLE, S.C., April 23 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN) has announced that the United States Patent and Trademark Office has awarded the Company a new and important patent entitled "System For, And Method Of, Monitoring Heartbeats Of A Patient". The patent, which covers 37 claims, will enhance the Company's ability to develop new proprietary products.

Patent attorneys from Fulwider & Patton supervised and executed the patent application along with Chief Technology Officer Budimir S. Drakulic -- the inventor of the patented technology. The new patent is owned by Signalife, Inc. In conjunction with the Patent Office's granting of the patent, the Company will now evaluate whether or not it will file a continuation or continuation-in-part application for the purpose of pursuing additional claim coverage in the technology that may have occurred since the time of the original application.

Budimir S. Drakulic called the patent-issuance-development a "major milestone in the continued proliferation and protection of the Company's core technologies and products." Dr. Drakulic continued to say that issued patents together with significant patent portfolio already submitted to the United States Patent Office and two Frost & Sullivan technology awards represent major achievements for a young medical device company.

The Company currently has several additional patents pending before the United States Patent and Trademark Office covering a wide array of cardiac technologies and products. Dr. Drakulic stated that he is "confident the Company will continue to be successful in obtaining approvals for pending patents of its technologies and products."

About Signalife

Signalife, Inc. is a life scienc
'/>"/>

SOURCE Signalife, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Signalife Announces Webcast
2. AMEX Notifies Signalife That It Has Accepted Signalifes Plan of Compliance
3. Signalife Sees Accretive Purchase and Financial Commitments
4. Signalife Wins Second Frost & Sullivan Technology Award
5. Signalife & Athletes Foundation Dispatch Mobile Health Center to Super Bowl
6. AMEX Notifies Signalife that It Will Need to Comply with Minimum Stockholders Equity Requirement
7. Signalife Presence at XIII World Congress on Cardiac Pacing and Electrophysiology
8. U.S. Patent 7,299,083 Awarded to Signalife
9. Signalife Receives FDA Clearance for OTC Non-Prescription Event Recorder Device
10. Signalife Continues to Procure Purchase Orders, Revenues
11. NFL Hall of Fame Legend Fred Biletnikoff Joins AFL/Signalife Cardiovascular Protection Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... May 21, 2015  CytRx Corporation (NASDAQ: ... specializing in oncology, today announced positive updated results ... aldoxorubicin for the treatment of unresectable glioblastoma multiforme ... open-label, multisite trial is designed to investigate the ... whose tumors have progressed following prior treatment with ...
(Date:5/21/2015)... May 21, 2015 Veolia’s environmental ... exclusive North American distribution agreement with VWR to ... , With more than 160 years of experience, ... services for laboratory and production facilities, has cultivated ... and differentiated services to enable science. Endetec’s ...
(Date:5/20/2015)... (PRWEB) May 20, 2015 This year ... especially for lawns. US Patented Pearl’s Premium Ultra ... lawns around the country that are coming out of ... addresses a number of major global concerns related to ... “non-grass” grass – the alternative to the standard, water-wasting, ...
(Date:5/20/2015)... , May 20, 2015  Health eCareers, ... short-staffed healthcare organizations with job seekers looking for ... , a new mobile and online tool dedicated ... healthcare industry. SHIFT enables employers to ... tenens, travel nursing, per diem and other temporary ...
Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2Breakthrough 4th Generation Low Maintenance Lawn Seed Offers Solution to California Drought 2Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 2Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 3
... Mass., May 26 Microtest Laboratories ... ICH stability testing , compliant with International Conference ... The testing is offered as part of Microtest,s ... product is submitted for regulatory approval, ICH stability testing ...
... Va. May 26 CEL-SCI Corporation (NYSE ... is developing an immune-based treatment for the "swine flu ... (Ligand Epitope Antigen Presentation System) vaccine technology. The ... has gained from developing protective and therapeutic vaccines utilizing ...
... China-Biotics, Inc.,(Nasdaq: CHBT ) ("China-Biotics", ... the manufacture, research, development, marketing and,distribution of ... Digestive Disease Week 2009 ("DDW 2009"). , ... (DDW) is the largest and most prestigious ...
Cached Biology Technology:Microtest Laboratories is an Industry Leader in ICH Stability Testing 2CEL-SCI Developing Immune-Based Treatment Against Swine and Other H1N1 Flu Viruses Using Proprietary L.E.A.P.S. Technology 2CEL-SCI Developing Immune-Based Treatment Against Swine and Other H1N1 Flu Viruses Using Proprietary L.E.A.P.S. Technology 3CEL-SCI Developing Immune-Based Treatment Against Swine and Other H1N1 Flu Viruses Using Proprietary L.E.A.P.S. Technology 4China-Biotics, Inc. to Attend Digestive Disease Week 2009 2
(Date:5/11/2015)... , May 11, 2015 Curemark LLC, a ... start of a new Phase III double blind, randomized, ... novel formulation, CM-AT, on all children ages 3-8 with ... FDA Phase III double blinded clinical trial for CM-AT ... levels of the digestive enzyme chymotrypsin. This new trial ...
(Date:5/7/2015)... May 7, 2015 Fingerprint ... FPC1022 and FPC1035, FPC,s smallest touch fingerprint sensors ... mainly considered for integration on the backside of ... OEMs increased possibilities to integrate touch fingerprint sensors ... also improves possibilities for module manufacturers to customize ...
(Date:4/27/2015)... , April 27, 2015  For more than four ... show has been the premier worldwide event for the ... is a must-attend event for any local, national, or ... the emerging commercial markets and current applications of unmanned ... of this projected $48 billion industry, and how it ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5
... enemy of the good, but in the nanoscale world, perfection can ... world, engineers and scientists go to great lengths to make the ... a light switch or turn the key on the car, we ... every time, with only rare exceptions. They have done so by ...
... (President Ryoji Noyori) and the Max Planck Society (MPG; ... 2011, to strengthen their collaboration by ,establishing a joint ... seeks to ,achieve a systematic understanding of biological systems ... research center will bring together the RIKEN Advanced Science ...
... that parents can fill out in pediatrician waiting rooms may ... disorder (ASD) , according to a study funded by the ... of Pediatrics , the study,s design also provides a model ... change to their practice. "Beyond this exciting proof of ...
Cached Biology News:Nanotechnologists must take lessons from nature 2Nanotechnologists must take lessons from nature 35-minute screen identifies subtle signs of autism in 1-year olds 2
... (OSM) is a pleiotropic cytokine produced by ... cells. OSM inhibits the growth of some ... smooth muscle and Kaposis sarcoma cell proliferation, ... density lipoprotein receptor expression on hepatoma cells. ...
... trinor Prostaglandin F2α isopropyl ester (15(R)-17-phenyl ... latanoprost-related isomer containing both a double ... (β) hydroxyl group at C-15. Similar ... ester is a potential impurity in ...
ACS Reagent Grade C 19 H 14 O 5 S Formula Weight: 354.38 PRODUCT SPECIFICATIONS Form: Rust/red crystalline powder Clarity of Solution: Passes test Visual Transition Interval: pH 6.8 - Yellow pH 8.2...
... Mouse Anti Nop1p/Fibrillarin (monoclonal) ... nucleolar protein of bakers yeast, Saccharomyces ... is essential for yeast viability and ... human homologue of Nop1p is fibrillarin ...
Biology Products: